GGrantIndex
← Leaderboards

Russell Barrett Van Dyke

Tulane University Of Louisiana

Google Scholar ↗PubMed ↗ORCID ↗
$24,377,705
Attributed
$25,956,645
Total exposure
50
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY2005–20
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$25,956,645 · 50

By mechanism

U01$21,908,662 · 3
R01$3,157,881 · 1
M01$890,102 · 46

Top collaborators

Most similar at Tulane University Of Louisiana

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectHiv InfectionsAids TherapyHuman Therapy EvaluationPediatric AidsAntiaids AgentCombination ChemotherapyDrug Screening /EvaluationChild (0-11)Human Immunodeficiency Virus 1AdolescentChildProtocols DocumentationVirus RnaMitochondrial DysfunctionAntiretroviral TherapyCohortPerinatalTransmission ProcessCardiacAcquired Immunodeficiency SyndromeClinical Trial Phase IExposure To

Grant awards (96)

Cardiac Toxicity in Perinatally HIV-Infected Adolescents and Young Adults, a Longitudinal Study$672,429
R01 · FY2020 · HL
Cardiac Toxicity in Perinatally HIV-Infected Adolescents and Young Adults, a Longitudinal Study$862,934
R01 · FY2019 · HL
Pediatric HIV/AIDS Cohort Study (PHACS) Coordinating Center (CC) (U01)$505,410
U01 · FY2019 · HD · contact PI
Pediatric HIV/AIDS Cohort Study (PHACS) Coordinating Center (CC) (U01)$1,058,764
U01 · FY2018 · HD · contact PI
Cardiac Toxicity in Perinatally HIV-infected Adolescents and Young Adults, a Longitudinal Study$729,481
R01 · FY2018 · HL
Pediatric HIV/AIDS Cohort Study (PHACS) Coordinating Center (CC) (U01)$1,073,131
U01 · FY2017 · HD · contact PI
Cardiac Toxicity in Perinatally HIV-infected Adolescents and Young Adults, a Longitudinal Study$893,037
R01 · FY2017 · HL
Pediatric HIV/AIDS Cohort Study (PHACS): Understanding Maternal HIV Disease through Pregnancy and the Postpartum Period and its Role in Child Health Outcomes$161,000
U01 · FY2017 · HD · contact PI
Pediatric HIV/AIDS Cohort Study (PHACS) Coordinating Center (CC) (U01)$1,072,848
U01 · FY2016 · HD · contact PI
Pediatric HIV/AIDS Cohort Study (PHACS) Coordinating Center (CC) (U01)$1,100,000
U01 · FY2015 · HD · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort Study II$980,687
U01 · FY2014 · HD · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort Study II$942,396
U01 · FY2013 · HD · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort Study II$977,455
U01 · FY2012 · HD · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort Study II$999,613
U01 · FY2011 · HD · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort Study II$1,091,768
U01 · FY2010 · HD · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort Study II$1,089,382
U01 · FY2010 · HD · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort S*$586,144
U01 · FY2009 · HD · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort S*$1,121,814
U01 · FY2008 · HD · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort S*$1,139,156
U01 · FY2007 · HD · contact PI
Tulane/LSU HIV/AIDS Clinical Trials Networks Unit$499,167
U01 · FY2007 · AI · contact PI
Coordinating Center for the Pediatric HIV/AIDS Cohort S*$1,030,195
U01 · FY2006 · HD · contact PI
Tulane/LSU Pediatric AIDS Clinical Trials Unit$531,585
U01 · FY2006 · AI · contact PI
ACTG 219: PEDIATRIC LATE OUTCOMES PROTOCOL$145,067
M01 · FY2006 · RR · contact PI
PACTG 1045: PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITIES IN HIV YOUTH$26,596
M01 · FY2006 · RR · contact PI
COMPARATIVE TRIAL OF PROTEASE-CONTAINING AND SPARING HAART REGIMENS IN HIV YOUTH$24,178
M01 · FY2006 · RR · contact PI
PACTG 1025: PERINATAL CORE PROTOCOL$13,702
M01 · FY2006 · RR · contact PI
STUDY OF COMBINATION ANTIRETROVIRAL REGIMENS AND TX-SWITCHING IN HIV+ CHILDREN$8,058
M01 · FY2006 · RR · contact PI
STUDY OF A NOVEL PROTEASE INHIBITOR (BMS232632) IN ART NAIVE HIV-INFECTED KIDS$5,641
M01 · FY2006 · RR · contact PI
HEPATITIS C PREVALENCE IN PERINATALLY INFECTED HIV-INFECTED CHILDREN$3,223
M01 · FY2006 · RR · contact PI
TRIAL OF THE SAFETY AND IMMUNOGENICITY OF FLUMIST IN HIV-INFECTED CHILDREN$2,418
M01 · FY2006 · RR · contact PI
STUDY OF HIGH DOSE LOPINAVIR/RITONAVIR IN HIV INFECTED PEDIATRIC SUBJECTS$805
M01 · FY2006 · RR · contact PI
Tulane/LSU Pediatric AIDS Clinical Trials Unit$852,164
U01 · FY2005 · AI
Coordinating Center for the Pediatric HIV/AIDS Cohort S*$816,527
U01 · FY2005 · HD
ACTG 219: PEDIATRIC LATE OUTCOMES PROTOCOL$104,189
M01 · FY2005 · RR
PACTG 1025: PERINATAL CORE PROTOCOL$15,588
M01 · FY2005 · RR
PACTG 1045: PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITIES IN HIV YOUTH$9,845
M01 · FY2005 · RR
STUDY OF COMBINATION ANTIRETROVIRAL REGIMENS AND TX-SWITCHING IN HIV+ CHILDREN$9,024
M01 · FY2005 · RR
STUDY OF A NOVEL PROTEASE INHIBITOR (BMS232632) IN ART NAIVE HIV-INFECTED KIDS$8,204
M01 · FY2005 · RR
COMPARATIVE TRIAL OF PROTEASE-CONTAINING AND SPARING HAART REGIMENS IN HIV YOUTH$4,513
M01 · FY2005 · RR
PACTG 402: TRIAL OF SUBCUTANEOUS IL-2 WITH HAART IN HIV-INFECTED CHILDREN$2,871
M01 · FY2005 · RR
ABACAVIR PHARMACOKINETICS DURING CHRONIC THERAPY IN HIV-1 INFECTED ADOLESCENTS$2,871
M01 · FY2005 · RR
TRIAL OF THE SAFETY AND IMMUNOGENICITY OF FLUMIST IN HIV-INFECTED CHILDREN$1,640
M01 · FY2005 · RR
ACTG 356: ZDV/3TC/NEVIRAPINE/1592U89 COMBINATION THERAPY IN HIV INFANTS AND KIDS$1,231
M01 · FY2005 · RR
THE EFFECTS OF HAART ON THE RECOVERY OF IMMUNE FUNCTION IN HIV-INFECTED CHILDREN$1,231
M01 · FY2005 · RR
ESTABLISHMENT AND MAINTENANCE OF LONG-TERM UNDETECTABLE PLASMA HIV-1 RNA$821
M01 · FY2005 · RR
Tulane/LSU Pediatric AIDS Clinical Trials Unit$895,978
U01 · FY2004 · AI
ACTG 219: Pediatric Late Outcomes Protocol$214,442
M01 · FY2004 · RR
PACTG 1025: PERINATAL CORE PROTOCOL$27,438
M01 · FY2004 · RR
PACTG 402: TRIAL OF SUBCUTANEOUS IL-2 WITH HAART IN HIV$20,216
M01 · FY2004 · RR
Study of a Novel Protease Inhibitor (BMS232632) in ART$16,607
M01 · FY2004 · RR
Study of Combination Antiretroviral Regimens$15,884
M01 · FY2004 · RR
Establishment and Maintenance of Long-Term Undetectable Plasma HIV-1 RNA$13,718
M01 · FY2004 · RR
The Effects of HAART on the Recovery of Immune Function in HIV-Infected Children$7,943
M01 · FY2004 · RR
HEPATITIS C PREVALENCE IN PERINATALLY INFECTED HIV$4,332
M01 · FY2004 · RR
Pharmacokinetic Interactions Between Depo-Provera &PIs$2,887
M01 · FY2004 · RR
ACTG 356: ZDV/3TC/Nevirapine/1592U89 Combination Therapy in HIV Infants and Kids$2,887
M01 · FY2004 · RR
TRIAL OF PROTEASE INHIBITOR-INCLUDING VERSUS SPARING$2,166
M01 · FY2004 · RR
Observational Study of Rate of Opportunistic Infections$1,445
M01 · FY2004 · RR
Evaluation of the Immunogenicity of Pneumococcal Vaccine$721
M01 · FY2004 · RR
Tulane/LSU Pediatric AIDS Clinical Trials Unit$814,570
U01 · FY2003 · AI
Tulane/LSU Pediatric AIDS Clinical Trials Unit$815,476
U01 · FY2002 · AI
TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT$884,360
U01 · FY2001 · AI
ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL$0
M01 · FY2001 · RR
LONG-TERM UNDETECTABLE PLASMA HIV-1 RNA$0
M01 · FY2001 · RR
INTERLEUKIN 2 IN HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
ZDV+3TC VERSUS DDI VERSUS ZDV+DDI IN HIV INFECTION$0
M01 · FY2001 · RR
GS97 418:DOSE LEVELS OF ADF &NELFINAVIR ADDED TO ANTIRETROVIRAL TREA$0
M01 · FY2001 · RR
PROAB3004:141W94 + CURRENT NUCLEOSIDE THERAPY VS CURRENT THERAPY ALON$0
M01 · FY2001 · RR
ACTG 397: 2 SAQUINAVIR CONTAINING COMBINATION TREATMENT REGIMENS IN H$0
M01 · FY2001 · RR
ACTG 366 RAD 1 ANTIRETROVIRAL MANAGEMENT ALGORITHM FOR PEDIATRIC HIV$0
M01 · FY2001 · RR
ACTG 377:PHASE II PRAM OF NOVEL ANTIRETROVIRAL THERAPY IN CHILDREN$0
M01 · FY2001 · RR
ACTG 382--SAFETY/TOLERABILITY/ANTIVIRAL ACTIVITY OF DMP266 + NELFINAVIR$0
M01 · FY2001 · RR
ACTG 247--INCREASED CALORIC DENSITY INFANT FORMULA &EFFECT ON GROWTH$0
M01 · FY2001 · RR
ACTG 356--ZDV/3TC/NEVIRAPINE/1592U89 COMBINATION THERAPY IN HIV INFANTS/CHILDREN$0
M01 · FY2001 · RR
ACTG 316--NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL/FETAL HIV$0
M01 · FY2001 · RR
ACTG338--NOVEL ANTIRETROVIRAL THERAPY IN STABLE EXPERIENCED HIV+ CHILDREN$0
M01 · FY2001 · RR
ACTG 254--PHASE II/III STUDY OF AT/AZ AS COMPARED TO TMP/SMX IN CHILDREN$0
M01 · FY2001 · RR
TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT$869,072
U01 · FY2000 · AI
ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL$11,180
M01 · FY2000 · RR
ACTG 254--PHASE II/III STUDY OF AT/AZ AS COMPARED TO TMP/SMX IN CHILDREN$11,180
M01 · FY2000 · RR
ACTG 185--PHASE III/HYPERIMMUNE ANTI-HIV IV IMMUNE GLOBULIN/MATERNAL-FETAL TRANS$11,180
M01 · FY2000 · RR
ACTG 230--PHASE I STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY/HIV/CHILDREN$11,180
M01 · FY2000 · RR
GS97 418:DOSE LEVELS OF ADF &NELFINAVIR ADDED TO ANTIRETROVIRAL TREA$11,180
M01 · FY2000 · RR
PROAB3004:141W94 + CURRENT NUCLEOSIDE THERAPY VS CURRENT THERAPY ALON$11,180
M01 · FY2000 · RR
ACTG 397: 2 SAQUINAVIR CONTAINING COMBINATION TREATMENT REGIMENS IN H$11,180
M01 · FY2000 · RR
ACTG 366 RAD 1 ANTIRETROVIRAL MANAGEMENT ALGORITHM FOR PEDIATRIC HIV$11,180
M01 · FY2000 · RR
ACTG 377:PHASE II PRAM OF NOVEL ANTIRETROVIRAL THERAPY IN CHILDREN$11,180
M01 · FY2000 · RR
ACTG 292:TRIAL OF SAFETY &IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE V$11,180
M01 · FY2000 · RR
ACTG 382--SAFETY/TOLERABILITY/ANTIVIRAL ACTIVITY OF DMP266 + NELFINAVIR$11,180
M01 · FY2000 · RR
ACTG 247--INCREASED CALORIC DENSITY INFANT FORMULA &EFFECT ON GROWTH$11,180
M01 · FY2000 · RR
ACTG 356--ZDV/3TC/NEVIRAPINE/1592U89 COMBINATION THERAPY IN HIV INFANTS/CHILDREN$11,180
M01 · FY2000 · RR
ACTG 316--NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL/FETAL HIV$11,180
M01 · FY2000 · RR
ACTG338--NOVEL ANTIRETROVIRAL THERAPY IN STABLE EXPERIENCED HIV+ CHILDREN$11,180
M01 · FY2000 · RR
LONG-TERM UNDETECTABLE PLASMA HIV-1 RNA$0
M01 · FY2000 · RR
INTERLEUKIN 2 IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ZDV+3TC VERSUS DDI VERSUS ZDV+DDI IN HIV INFECTION$0
M01 · FY2000 · RR